* Disclaimer:  Our products and technologies are currently not available for clinical use. FDA or other regulatory agencies have not evaluated the statements on this website regarding our products and technologies. 

Theragnostic Technologies Selected for the Prestigious NIH Commercialization Accelerator Program

October 15, 2015

Theragnostic Technologies Inc has been selected for prestigious NIH Commercialization Accelerator Program (CAP). CAP offered annually since 2004 is designed to help some of  NIH’s most promising healthcare Phase II grantees. Applicants are selected via a competitive process for a limited number of slots. The program will help advance the commercial development of our first product ManGraDex - a novel high performance imaging platform. Click read more for information about NIH's Commercialization Accelerator Program.

 

 

 

READ FULL ARTICLE >

Please reload

Recent Posts
Please reload